View |
BR-1324_PI_01.pdf
|
BR-1324
|
Somatropin
|
Genotropin GoQuick
|
12 mg/mL
|
Powder and Solvent for Solution for Injection (SC)
|
Anterior Pituitary Lobe Hormones and Analogues
|
Pfizer Manufacturing Belgium N.V.
|
Belgium
|
Monitored Release (MR) (Reconstruction) `
|
22 February 2024
|
16 July 2025
|
View |
BR-1325_PI_01.pdf
|
BR-1325
|
Somatropin
|
Genotropin GoQuick
|
5.3mg/mL
|
Powder and Solvent for Solution for Injection (SC)
|
Anterior Pituitary Lobe Hormones and Analogues
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
Monitored Release (MR) (Reconstruction) `
|
22 February 2024
|
16 July 2025
|
View |
BR-1326_PI_01.pdf
|
BR-1326
|
Semaglutide
|
Ozempic
|
1 mg/0.74mL (1.34mg/mL)
|
Solution For Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (Variation)
|
17 November 2022
|
17 November 2027
|
View |
BR-1327_PI_01.pdf
|
BR-1327
|
Semaglutide
|
Ozempic
|
0.5 mg/0.37 mL (1.34 mg/mL)
|
Solution for Injection (SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
Monitored Release (Variation)
|
28 October 2022
|
28 October 2027
|
View |
BR-1328_PI_01.pdf
|
BR-1328
|
Semaglutide
|
Ozempic
|
0.25 mg/0.19 mL (1.34 mg/mL)
|
Solution for Injection
(SC)
|
-
|
Novo Nordisk A/S
|
Denmark
|
-
|
29 September 2020
|
29 September 2025
|
View |
|
BR-220
|
Rabbies Vaccine (Inactivated)(Wistar Strain Rabies)
|
Verorab
|
2.5 IU/ 0.5 mL
|
Powder For Suspension(ID/IM)
|
-
|
Sanofi Pasteur, Inc.
|
France
|
Renewal
|
26 May 2023
|
10 December 2027
|
View |
|
BR-280
|
Typhoid Polysaccharide Vaccine
|
Typhim Vi
|
Formulation: Each dose (0.5 mL) contains: Purified Vi capsular polysaccharide of Salmonella typhi (Ty2 strain)...................... 25 mcg
|
Solution for Injection (IM/SC)
|
-
|
Sanofi Pasteur
|
France
|
-
|
18 March 2022
|
01 March 2027
|
View |
|
BR-289
|
Rabbit Anti-Human Thymocyte Immunoglobulin
|
Thymoglobuline
|
5 mg/mL
|
Powder for Solution for Infusion (IV)
|
-
|
Genzyme Polyclonal S.A.S.
|
France
|
Regular Renewal (Compliance)
|
30 March 2022
|
08 February 2026
|
View |
|
BR-307
|
Hepatitis B Immunoglobulin (Human)
|
Hepabig
|
200 IU/mL
|
Solution For Injection
|
Immunoglobulin
|
Green Cross Corporation
|
Korea
|
Renewal
|
07 April 2022
|
22 March 2027
|
View |
|
BR-324
|
Diphtheria-Tetanus Toxoids And Pertussis ( DTP ) Vaccines
|
Perdinus
|
30 IU (25 Lf) / 40 IU (5 Lf) / 4 IU per 0.5 mL
|
Suspension for Injection (IM) (Monodose)
|
-
|
Serum Institute of India Private Limited
|
India
|
-
|
26 February 2021
|
28 December 2025
|
View |
|
BR-325
|
Diphtheria-Tetanus Toxoid ( DT )
|
Ditevac
|
30 IU/ 40 IU per 0.5 mL
|
Suspension for Injection (IM) (Pediatric-Single Dose)
|
VACCINE
|
Serum Institute of India Ltd.
|
India
|
Renewal
|
10 August 2021
|
27 September 2026
|
View |
|
BR-326
|
Tetanus Toxoid (Adsorbed)
|
T-Vac
|
5 Lf per 0.5mL
|
Suspension for Injection (IM)
|
VACCINE
|
Serum Institute of India Ltd.
|
India
|
Automatic Renewal
|
10 August 2021
|
07 July 2026
|
View |
|
BR-334
|
Hepabig
|
Hepatitis B Immunoglobulin (Human)
|
100 IU/0.5 mL
|
Solution For Injection
|
Immunoglobulin
|
Green Cross Corporation
|
Korea
|
Renewal
|
19 April 2022
|
06 April 2027
|
View |
|
BR-349
|
Measles Vaccine (Live, Attenuated)
|
M-Vac
|
None
|
Lyophilized Powder for Injection (SC)
|
Vaccines
|
Serum Institute of India Pvt., Ltd.
|
India
|
Initial (Variation)
|
27 February 2024
|
27 February 2029
|
View |
|
BR-359
|
Clostridium botulinum Type A Neurotoxin Complex
|
Botox
|
100 Units
|
Lyophilized Powder for Injection (IM)
|
-
|
Allergan Pharmaceuticals Ireland
|
Ireland
|
Regular Renewal
|
26 February 2021
|
26 September 2025
|
View |
|
BR-409
|
Factor IX Complex
|
Profilnine SD
|
1000 IU/10mL
|
Iv
|
Plasma Fraction for Specific Use
|
Grifols Biologicals Inc.
|
U.S.A
|
Renewal
|
09 August 2019
|
05 October 2028
|
View |
|
BR-411
|
Factor IX Complex
|
Profilnine SD
|
500 IU/5mL%
|
Iv
|
Plasma Fraction for Specific Use
|
Grifols Biologicals Inc.
|
U.S.A
|
Renewal
|
09 August 2019
|
16 October 2028
|
View |
|
BR-415
|
Measles, Mumps, Rubella (MMR) Vaccine (Live, attenuated) [see formulation on reverse side]
|
Priorix
|
After reconstitution, each dose (0.5mL) contains:
Measles virus (Schwarz strain), live attenuated NLT 10 3.0 CCID 50
Mumps virus (RIT4385 strain), live attenuated NLT 10 3.7 CCID 50
Rubella virus (Wistar RA 27/3 strain), live attenuated NLT 10 3.0 CCID 50
|
Powder for Solution for Injection (SC)
|
-
|
GSK Biologicals SA
|
Belgium
|
-
|
30 March 2021
|
04 May 2026
|
View |
|
BR-434
|
Measles, Mumps and Rubella Vaccine (Live, Attenuated)
|
Tresivac
|
Formulation: After reconstitution, one dose (0.5 mL) contains: Measles Virus-NLT 1,000 CCID 50 Mumps Virus-NLT 5,000 CCID 50 Rubella Virus -NLT 1,000 CCID 50
|
Freeze-dried Powder for Suspension for Injection (SC)
|
-
|
Serum Institute of India Private Limited
|
India
|
Initial (Variation)
|
04 October 2022
|
04 October 2027
|
View |
|
BR-435
|
Tetanus Toxoid ( Adsorbed )
|
T-Vac
|
5Lf per 0.5mL
|
Suspension For Injection (I.M)
|
-
|
Serum Institue of India Private Limited
|
India
|
-
|
18 March 2022
|
07 July 2026
|